Supplemental animal reports have recommended that these opioid-receptor consequences could possibly be reversible with the opioid antagonist naloxone. Although cannabis (cannabis) remains a federal DEA Plan one controlled material, analysis has resulted in development and promoting of remedies that are synthetic prescription cannabinoid products